Sutro Self: $500M Celgene Tie to 'Kick Tires' in ADC, More
By Randy Osborne
Wednesday, December 19, 2012
The potential $500 million deal signed by Sutro Biopharma Inc. with Celgene Corp. includes two undisclosed targets against which antibody conjugates and bispecific antibodies will be deployed, plus the manufacturing of a Celgene-owned antibody, as the latter company explores Sutro's platform in multiple areas.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.